IN

Incanthera plc

A therapeutics company developing targeted solutions for dermatology and oncology.

INC | Aquis Stock Exchange

Overview

Corporate Details

ISIN(s):
GB00BGL7YW15 (+1 more)
LEI:
2138002HEV4UFBOEXQ97
Country:
United Kingdom
Address:
C/O GATELEY LEGAL, M2 4WU MANCHESTER

Description

Incanthera plc is a therapeutics company specializing in the discovery and development of targeted solutions for dermatology and oncology. The company develops and applies sophisticated formulation and delivery technologies to create novel treatments. Its pipeline includes clinical-stage oncology assets intended for licensing to pharmaceutical partners. Incanthera has also commercialized its dermatological expertise through its direct-to-consumer skincare brand, Skin+CELL, which is designed to address unmet needs in the skincare market.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2024-04-09 16:00
Exercise of Warrants
English 23.1 KB
2024-03-25 15:30
Initiation of Analyst Research and IGTV Interview
English 23.0 KB
2024-03-25 08:00
Commercial Update
English 32.8 KB
2024-02-22 08:00
Grant of Options
English 33.8 KB
2024-01-11 08:00
Holding(s) in Company
English 21.6 KB
2023-12-21 08:00
Half-year Report
English 176.6 KB
2023-12-18 08:00
Commercial Deal, Subscription and Conversion
English 31.6 KB
2023-11-08 14:20
Result of AGM
English 15.9 KB
2023-10-03 08:48
Notice of AGM and Posting of Accounts
English 20.3 KB
2023-10-02 08:00
Final Results
English 282.5 KB
2023-08-21 08:00
Warrant Extension
English 21.0 KB
2023-07-20 08:00
Further re: Director's Dealing
English 34.1 KB
2023-04-05 13:04
Result of Warrant Holder Meeting
English 19.5 KB
2023-03-30 08:00
Further re: Director's Dealing
English 21.4 KB
2023-03-13 08:00
Director’s Dealing and Proposed Warrant Extension
English 40.2 KB

Automate Your Workflow. Get a real-time feed of all Incanthera plc filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Incanthera plc

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Incanthera plc via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.